Article thumbnail

Genome response to tissue plasminogen activator in experimental ischemic stroke

By Glen C Jickling, Xinhua Zhan, Bradley P Ander, Renée J Turner, Boryana Stamova, Huichun Xu, Yingfang Tian, Dazhi Liu, Ryan R Davis, Paul A Lapchak and Frank R Sharp
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2875237
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2008). 5 hours after acute ischemic stroke.
  2. (2006). Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology
  3. (2006). Atorvastatin downregulates tissue plasminogen activator-aggravated genes mediating coagulation and vascular permeability in single cerebral endothelial cells captured by laser microdissection. J Cereb Blood Flow Metab
  4. (2003). Bordet R: Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function. Stroke
  5. (2008). et al.: Synergistic effect of an endothelin type A receptor antagonist, S-with rtPA on the neuroprotection after embolic stroke. Stroke
  6. (2006). Florquin S: Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury.
  7. (2001). FR: Blood genomic responses differ after stroke, seizures, hypoglycemia, and hypoxia: blood genomic fingerprints of disease. Ann Neurol
  8. (2006). FR: Genomic profiles for human peripheral blood T cells, B cells, natural killer cells, monocytes, and polymorphonuclear cells: comparisons to ischemic stroke, migraine, and Tourette syndrome. Genomics
  9. (2007). GA: Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat.
  10. (2006). Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: a microarray study. J Cereb Blood Flow Metab
  11. (2008). Gene expression in peripheral blood differs after cardioembolic compared with large-vessel atherosclerotic stroke: biomarkers for the etiology of ischemic stroke.
  12. Lindsberg PJ: An emerging role of mast cells in cerebral ischemia and hemorrhage.
  13. (2007). Lindsberg PJ: Mast cell stabilization reduces hemorrhage formation and mortality after administration of thrombolytics in experimental ischemic stroke. Circulation
  14. (2003). Lo EH: Lipoprotein receptormediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med
  15. (2004). Lo EH: Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke
  16. (2009). Neutrophils contribute to intracerebral haemorrhages after treatment with recombinant tissue plasminogen activator following cerebral ischaemia.
  17. (2008). Nighoghossian N: Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update.
  18. (2002). Pre-validation and inference in microarrays. Stat Appl Genet Mol Biol
  19. (2007). Raghubir R: Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev
  20. (2009). Recanalization and reperfusion therapies for acute ischemic stroke. Cerebrovasc Dis
  21. (1989). Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke
  22. (1999). SC: Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model. Stroke
  23. (2008). Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release.
  24. (2008). Tissue plasminogen activator enhances the hypoxia/reoxygenation-induced impairment of the blood-brain barrier in a primary culture of rat brain endothelial cells. Cell Mol Neurobiol
  25. (2009). Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci
  26. (2003). Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein.
  27. (2003). TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics
  28. (2005). TS: Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am J Physiol Heart Circ Physiol
  29. (2005). Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: a pilot investigation. Circulation
  30. (2008). Warach S: Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke. Cerebrovasc Dis
  31. (2007). Wijman CA: Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis
  32. (2009). Wong B: Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy. Pharmacogenomics J
  33. (2000). Zivin JA: Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke
  34. (1999). Zivin JA: Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. Stroke